RxDoctor Payments Data

Paul Liederman, MD

Psychiatry · Santee, CANPI 1942237532

Payments from drug & device makers

$3,058in general payments, 2019–2025

Across 141 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$573
  • Sunovion Pharmaceuticals Inc.$411
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$356
  • Otsuka America Pharmaceutical, Inc.$287
  • Johnson & Johnson$269
  • Supernus Pharmaceuticals, Inc.$230
  • plus $933 from 15 others

What the payments were for

  • Food & beverage$3,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,058 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$162,547
Medicare patients
97
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$98,778
RexultiBrexpiprazole23$31,514
Risperdal ConstaRisperidone Microspheres24$24,003
Lurasidone Hcl60$15,312
FanaptIloperidone13$14,288
Clozapine119$8,106
Fluvoxamine Maleate128$5,192
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl26$5,093
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$4,505
Risperidone224$3,597
Benztropine Mesylate173$3,576
Divalproex Sodium ErDivalproex Sodium38$2,664
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine38$2,368
Trazodone Hcl231$2,250
Prazosin Hcl54$2,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$62$98,77820 claims
Otsuka America Pharmaceutical, Inc.Rexulti$287$31,51423 claims
Johnson & JohnsonRisperdal Consta$269$24,00324 claims
Vanda Pharmaceuticals Inc.Fanapt$573$14,28813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santee

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →